David McCarty

Serve as a subject matter expert in real-world, patient-level healthcare data to guide and inform business cases for Life Science Companies' HEOR, Medical Affairs, Pharmacoepidemiology, and Commercial Analytic teams. Leverage R&D and Venture experience to help clients build Value and ROI propositions in support of driving multi-million dollar revenue growth through new and recurring data license engagements. Built AI-empowered reference tools to improve team efficiency in data exploration, market analysis, and response to client-submitted RFIs/RFPs.

Provide Optum healthcare data consultation services to Life Sciences companies and support Optum's Business Development Executives through contract life cycles. Serve as a subject matter expert in both the acquisition and applicability of real-world healthcare data (clinical and claims). Perform data feasibilities to ensure data licenses are fit for research purposes and serve as primary point of client contact for data enrichment and research support services.

Led our immunology research portfolio with a focus on leveraging existing and novel health data streams to improve patient experience and outcomes in the space of rare and autoimmune diseases. Served as a subject matter expert and liaison between UHG R&D's executive leadership and venture groups and our external industry, academic, and clinical collaborators. Drafted and presented research theses that served as the foundation for our investments into novel diagnostic and clinical care programs and technologies that could accelerate the practice of disease interception and personalized first-line therapy selection. Managed a multi-million dollar research budget and vendor contracts, designed clinical study protocols through IRB approval, and consulted on value-based and shared-savings contracting and key outcomes measures.

Acquired by UnitedHealth Group

Primary research objectives included the biological characterization and validation of mechanisms of action of novel drug analogs for the treatment of advanced stages of prostate cancer Performed in vitro and in vivo comparative drug intervention studies using immortalized cancer cell lines and xenograft mouse models Ran and optimized research protocols to evaluate gene and protein expression changes following targeted action of aberrant cellular signaling pathways that promote tumor growth and metastases Assessed utility of new research technologies and assays for improving work-throughput Promoted open discussion and peer-review of scientific findings throughout all stages of project completion

Primary responsibilities included the evaluation of new technologies and composition of technical summaries for UM Ventures and Scientific Review Committees Ongoing objectives encompassed establishing an understanding of critical features for securing patent protection of intellectual property as well as identifying consumers and industry partners within key markets for commercialization

Primary research focus was to assess the role of JAK3 signaling in the modulation of lymphocytic activation, maturation, and response for the development of autoimmune Type 1 Diabetes Mellitus (T1DM) Ongoing objectives include the use of pharmacological agents to inspire a T-regulatory cell reduction of T1DM incidence in high-risk patients